NSCLC patients harbouring rare or complex EGFR mutations are more often smokers and might not benefit from first-line tyrosine kinase inhibitor therapy
Respiration Dec 06, 2017
Kauffmann-Guerrero D, et al. - Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations were assessed in this study to determine the characteristics as well as the prognosis and the response to tyrosine kinase inhibitor (TKI) treatment in these subjects. In terms of smoking status and response to TKIs, differences were noted between patients with rare or complex EGFR mutations and those with classic mutations. Furthermore, automatic selection of first-line TKIs based on the sole presence of an EGFR mutation was not recommended as these mutations may not respond well to TKI therapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries